Stockreport

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pyxis Oncology, Inc.  (PYXS) 
PDF - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objectiv [Read more]